Novo Nordisk to end business tie-up with Dalim

Published: 2008-03-12 06:56:00

Updated: 2008-03-12 06:56:00

Novo Nordisk Pharma Korea, a Korean Unit of Novo Nordisk in Demark, says it agreed to terminate its 25-year business relationship with Dalim Corporation over the local distribution of conventional human insulin preparations - Insuratard Human Insulin and Mixtard Human Insulin.

Under the agreem...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK